Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00151398
Status:
COMPLETED
Last Update Posted:
2022-05-06
First Post:
2005-09-06
Brief Title:
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimers Disease AD
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A 3-Month Randomized Double-Blind Placebo-Controlled Multicenter Safety Tolerability and Efficacy Study Of 3 Doses Of Lecozotan SRA-333 SR In Outpatients With Mild To Moderate Alzheimers Disease With Donepezil As Active Control
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is determine the safety tolerability and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimers Disease over 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B343-1057 B343-1058 | OTHER | Pfizer | None |